{
    "clinical_study": {
        "@rank": "126069", 
        "arm_group": [
            {
                "arm_group_label": "Insulin degludec/liraglutide, B5", 
                "arm_group_type": "Experimental", 
                "description": "Subjects will be randomly allocated to the two single dose administrations (one for each of the two IDegLira formulations) on the two separate dosing visits. The two administration days will be separated by a wash-out period of 7-15 days."
            }, 
            {
                "arm_group_label": "Insulin degludec/liraglutide, V2", 
                "arm_group_type": "Experimental", 
                "description": "Subjects will be randomly allocated to the two single dose administrations (one for each of the two IDegLira formulations) on the two separate dosing visits. The two administration days will be separated by a wash-out period of 7-15 days."
            }
        ], 
        "brief_summary": {
            "textblock": "This trial is conducted in Europe. The aim of this trial is to assess the expected\n      biological equivalence between two formulations of insulin degludec/liraglutide (IDegLira)\n      with identical active ingredient in healthy volunteers."
        }, 
        "brief_title": "A Trial to Demonstrate Bioequivalence Between Two Insulin Degludec/Liraglutide Formulations, B5 and V2 in Healthy Subjects", 
        "completion_date": {
            "#text": "November 2013", 
            "@type": "Actual"
        }, 
        "condition": [
            "Diabetes", 
            "Diabetes Mellitus, Type 2", 
            "Healthy"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy male and female volunteers\n\n          -  Body mass index (BMI) between 18.5 and 27.0 kg/m^2 (both inclusive)\n\n          -  Body weight between 60 and 90 kg (both inclusive)\n\n        Exclusion Criteria:\n\n          -  Female of child-bearing potential who is pregnant, breast-feeding or intend to become\n             pregnant or is not using adequate contraceptive methods. Adequate contraceptive\n             measures are implants, injectables, combined oral contraceptives, hormonal\n             intrauterine device, sexual abstinence or vasectomised partner\n\n          -  History or presence of cancer, or any clinically significant cardiovascular,\n             respiratory, metabolic, renal, hepatic, gastrointestinal, endocrine (incl. diabetes),\n             haematological, dermatological, venereal, neurological, psychiatric diseases or other\n             major disorders\n\n          -  Use of any prescription or non-prescription medication, except for paracetamol,\n             acetylsalicylic acid, contraceptives and vitamins (but including mega-dose vitamin\n             therapy, as judged by the investigator) within 2 weeks before the trial\n\n          -  Drug or alcohol abuse"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 2, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01916174", 
            "org_study_id": "NN9068-4026", 
            "secondary_id": [
                "2012-005468-93", 
                "U1111-1137-3809"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "Insulin degludec/liraglutide, B5", 
                "description": "Subject will receive a single injection (s.c.) of IDegLira B5", 
                "intervention_name": "insulin degludec/liraglutide", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Insulin degludec/liraglutide, V2", 
                "description": "Subject will receive a single injection (s.c.) of IDegLira V2", 
                "intervention_name": "insulin degludec/liraglutide", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Insulin", 
                "Glucagon-Like Peptide 1"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "November 7, 2013", 
        "link": {
            "description": "Clinical Trials at Novo Nordisk", 
            "url": "http://novonordisk-trials.com"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Neuss", 
                    "country": "Germany", 
                    "zip": "41460"
                }
            }
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Trial to Demonstrate Bioequivalence Between Two Insulin Degludec/Liraglutide Formulations, B5 and V2 in Healthy Subjects", 
        "overall_official": {
            "affiliation": "Novo Nordisk A/S", 
            "last_name": "Global Clinical Registry (GCR, 1452)", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "November 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Area under the serum IDeg concentration time curve after single dose", 
                "safety_issue": "No", 
                "time_frame": "Assessed from 0 to 120 hours"
            }, 
            {
                "measure": "Maximum observed serum IDeg concentration after single dose", 
                "safety_issue": "No", 
                "time_frame": "Assessed from 0-120 hours"
            }, 
            {
                "measure": "Area under the plasma liraglutide concentration time curve after single dose", 
                "safety_issue": "No", 
                "time_frame": "Assessed from 0-72 hours"
            }, 
            {
                "measure": "Maximum observed plasma liraglutide concentration after single dose", 
                "safety_issue": "No", 
                "time_frame": "Assessed from 0-72 hours"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01916174"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Area under the serum IDeg concentration time curve after single dose", 
                "safety_issue": "No", 
                "time_frame": "Assessed from 0-120 hours"
            }, 
            {
                "measure": "Time to maximum IDeg concentration", 
                "safety_issue": "No", 
                "time_frame": "Assessed from 0-120 hours"
            }, 
            {
                "measure": "Terminal elimination half-life for IDeg after single dose", 
                "safety_issue": "No", 
                "time_frame": "Assessed from 0-120 hours"
            }, 
            {
                "measure": "Area under the plasma liraglutide concentration time curve after single dose", 
                "safety_issue": "No", 
                "time_frame": "Assessed from 0-72 hours"
            }, 
            {
                "measure": "Time to maximum plasma liraglutide concentration after single dose", 
                "safety_issue": "No", 
                "time_frame": "Assessed from 0-72 hours"
            }, 
            {
                "measure": "Terminal elimination half-life of liraglutide after single dose", 
                "safety_issue": "No", 
                "time_frame": "Assessed from 0-72 hours"
            }
        ], 
        "source": "Novo Nordisk A/S", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novo Nordisk A/S", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}